ARGX Share Price Performance
€0
-460.40 (-100.00%)
Price €0
Fair Value€869.07
Share Pricen/a
Narrative Update • Jun 30
argenx SE Stock Price
- 4 Narratives written by author
- 0 Comments on narratives written by author
- 78 Fair Values set on narratives written by author
ARGX Community Narratives
AN
Fair Value
·Fair Value €869.07 4.4% undervalued intrinsic discount
ARGX: Upcoming Phase 3 Readouts and Expanded Access Will Shape Future Outlook
0users have liked this narrative
0users have commented on this narrative
32users have followed this narrative
KA
Fair Value
·Fair Value €686.43 21.0% overvalued intrinsic discount
High-growth biotech compounding story if VYVGART becomes a multi-indication platform drug
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value €644.9 28.8% overvalued intrinsic discount
Rising Pricing Pressures And Biosimilar Challenges Will Weaken Margins
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
High-growth biotech compounding story if VYVGART becomes a multi-indication platform drug
argenx is betting that its lead drug VYVGART can move beyond one rare disease and become a platform treatment across several autoimmune conditions. The upside comes from a steady stream of upcoming study results and new uses, but the story can also break if trials disappoint or drug-pricing pressure intensifies.Read more
ARGX: Upcoming Phase 3 Readouts and Expanded Access Will Shape Future Outlook
argenx is pushing its lead autoimmune drug into more uses and more countries, with a self‑injection option that could make it easier for patients to start and stay on treatment. The big question is whether growing competition and tougher rules around drug pricing and insurance coverage start to squeeze what the company can earn.Read more
AN
€869.07
4.4% undervalued intrinsic discount
Fair Value
Revenue
22.98% p.a.
Profit Margin
34.98%
Future PE
24.41x
Price in 2029
€1.02k
Rising Pricing Pressures And Biosimilar Challenges Will Weaken Margins
argenx leans heavily on its Vyvgart medicine, and growing pushback on drug pricing plus copycat alternatives could squeeze what it earns on each patient over time. At the same time, new treatments in development and investments in making and delivering its drugs could help it rely less on one product and keep growth going.Read more
AN
€644.9
28.8% overvalued intrinsic discount
Fair Value
Revenue
19.67% p.a.
Profit Margin
27.34%
Future PE
25.51x
Price in 2029
€754.53
AI Collaboration And Aging Trends Will Expand Autoimmune Biologics Markets
argenx’s lead treatment for autoimmune disease is catching on faster than many expected, helped by an easier way to take it and new uses rolling out in more countries. The bigger story is whether its new AI-aided research push and growing demand from an aging population can keep growth going even as pricing, regulators, and new rivals raise the stakes.Read more
AN
€991
16.2% undervalued intrinsic discount
Fair Value
Revenue
30.18% p.a.
Profit Margin
38.14%
Future PE
21.92x
Price in 2029
€1.16k
Trending Discussion
Recently Updated Narratives
KA
High-growth biotech compounding story if VYVGART becomes a multi-indication platform drug
Fair Value: €686.43 21.0% overvalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ARGX: Myositis Phase 3 Readouts Will Shape Future Earnings Power
Fair Value: €869.07 4.4% undervalued intrinsic discount
32 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ARGX: Phase 3 Myositis And ALKIVIA Outcomes Will Test Elevated Stock Expectations
Fair Value: €644.9 28.8% overvalued intrinsic discount
5 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
argenx SE Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Jul 23, 2026
- 23.94
- 58.11%
- 31.40%
- 0.6%
About ARGX
- Founded
- 2008
- Employees
- 1863
- CEO
- WebsiteView website
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Recent ARGX News & Updates
Narrative Update • Jun 16
